RESEARCH TRIANGLE PARK, N.C. – May 31, 2012 – Quintiles today issued the first of three white papers on the expanding role of modeling and simulation across the drug development lifecycle. “Lifecycle Modeling and Simulation: Current Practice and Future Impact on Healthcare Innovation and Delivery” discusses the potential of modeling and simulation to advance healthcare delivery through applications in drug development. It is available for download at http://www.quintiles.com/perspectives/.

“Modeling and simulation is still in its infancy in biopharmaceutical development and healthcare management, but it has the potential to expand knowledge to increase efficiencies in clinical research and to inform healthcare policy and decision making,” said Michael O’Kelly, Senior Director, Center for Statistics in Drug Development at Quintiles. “Drug development is a high-risk enterprise with poor predictability. Modeling and simulation can be an invaluable tool to ‘discharge risk’ through better planning and design, and to explore and quantify risks to make clinical research more informative and efficient.”

Quintiles’ white paper addresses how new modeling and simulation applications range from genetics studies and identifying drug targets to simulated clinical trials. It covers how modeling and simulation can test assumptions and make predictions that improve planning and decision-making across the full spectrum of therapeutic innovation, and how it enriches and quantifies scientific thinking by bringing experts together to consider optimal approaches.

Andrew Garrett, Vice President of Global Biostatistics, Medical Writing and Regulatory Affairs at Quintiles said: “Quintiles is on the forefront of leveraging modeling and simulation to help our customers better characterize risk and identify opportunities to optimize outcomes. More real-world health data, together with greater computational power, are making it possible to build models and perform simulations that address healthcare’s toughest ‘what-if’ questions, like what is the likely economic impact of one intervention compared to another.”

The second paper in the series will address modeling and simulation applications specific to Phases I to III, including trial design, dosing and portfolio management. The third will address new frontiers for modeling and simulation in late stage development, commercialization and outcomes evaluation.

Quintiles’ modeling and simulation solutions provide customers with the expertise and resources to give their molecules, studies and overall portfolio the best chance of success. For information on Quintiles’ model-based drug development services, visit http://www.quintiles.com/mbdd.

About Quintiles

Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. Our network of more than 25,000 professionals in 60 countries has an eye on the future while delivering results today with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies develop and commercialize products to improve and lengthen patients’ lives while demonstrating value to stakeholders. Visit www.quintiles.com for more information and www.quintiles.com/news for additional company news.